Advanced Cervical Cancer: Quantitative Assessment of Early Response with Intravoxel Incoherent Motion Diffusion-weighted Magnetic Resonance Imaging after Neoadjuvant Chemotherapy

Nowadays, Neoadjuvant chemotherapy (NACT) of cervical cancer is widely employed in clinical. The aim of NACT is to reducing the tumor size and eliminating latent/micro lymph node metastases or improving radiation sensitivity before surgery or radiotherapy. Unfortunately, the cancer progressed in some patients and the responded rate of NACT in cervical cancer only ranges from 65% to 87.5% . Non-responded NACT may increase the risk of tumor progression and surgical difficulty, and the response to NACT can be considered as an independent prognostic factor . When non-responded NACT occurs by RECISTs, modifying the treatment strategy has to be considered, including earlier surgery or radiation therapy . It does really need good early predictors to evaluate NACT respondents before RECISTs.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.